<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436930</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000530026</org_study_id>
    <secondary_id>HOAG-HCC-06-03</secondary_id>
    <nct_id>NCT00436930</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma</brief_title>
  <official_title>Randomized Phase II Trial of Autologous Vaccines Consisting of Adjuvant GM-CSF Plus Proliferating Tumor Cells Versus GM-CSF Plus Dendritic Cells Loaded With Proliferating Tumor Cells in Patients With Metastatic Melanoma (MAC-VAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body&#xD;
      build an effective immune response to kill tumor cells. Colony-stimulating factors, such as&#xD;
      GM-CSF, increase the number of white blood cells and platelets found in bone marrow or&#xD;
      peripheral blood. Giving vaccine therapy together with GM-CSF may be an effective treatment&#xD;
      for melanoma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying two different vaccine therapy regimens to&#xD;
      compare how well they work when given together with GM-CSF in treating patients with&#xD;
      recurrent or metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare overall survival, progression-free survival, event-free survival, and&#xD;
           failure-free survival of patients with metastatic melanoma treated with vaccine therapy&#xD;
           comprising irradiated autologous tumor cells vs autologous dendritic cells loaded with&#xD;
           irradiated autologous tumor cells in combination with sargramostim (GM-CSF).&#xD;
&#xD;
        -  Compare the frequency of immune response based on delayed-type hypersensitivity to&#xD;
           irradiated autologous tumor cells and serologic and cellular assays at baseline and&#xD;
           during and after completion of autologous tumor cell-based vaccine therapy in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to measurable disease&#xD;
      (yes vs no) and location of disease (distant vs regional). Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive irradiated autologous tumor cells subcutaneously (SC) and&#xD;
           sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5&#xD;
           months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive autologous dendritic cells loaded with irradiated autologous&#xD;
           tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5&#xD;
           months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival, progression-free survival, event-free survival, and failure-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of immune response as measured by delayed-type hypersensitivity and serologic and cellular assays at baseline and during and after completion of study treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of melanoma&#xD;
&#xD;
               -  Regionally recurrent or distant metastatic disease&#xD;
&#xD;
          -  Must have an established continuously proliferating cell line expanded to about 200&#xD;
             million cells that is free of stromal cells and contamination&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
               -  Prior treatment for brain metastases or spinal cord compression allowed&#xD;
&#xD;
               -  No clear evidence of disease progression in the CNS&#xD;
&#xD;
               -  No concurrent pharmacologic doses of corticosteroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 70-100% OR ECOG PS 0-1&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mmÂ³&#xD;
&#xD;
          -  Hematocrit &gt; 30%&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Albumin &gt; 3.0 mg/dL&#xD;
&#xD;
          -  No significant hepatic or renal dysfunction&#xD;
&#xD;
          -  No other invasive cancer within the past 5 years&#xD;
&#xD;
          -  No active infection or other active medical condition that could be eminently life&#xD;
             threatening, including any of the following:&#xD;
&#xD;
               -  Active blood clotting&#xD;
&#xD;
               -  Bleeding diathesis&#xD;
&#xD;
          -  No ongoing transfusion requirement&#xD;
&#xD;
          -  No underlying cardiac disease associated with known myocardial dysfunction&#xD;
&#xD;
          -  No unstable angina related to atherosclerotic cardiovascular disease&#xD;
&#xD;
          -  No known autoimmune disease&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior surgery, radiotherapy, chemotherapy, biological therapy (including sargramostim&#xD;
             [GM-CSF]), or vaccine therapy allowed&#xD;
&#xD;
          -  No concurrent anticancer therapy (e.g., hormone therapy for prostate or breast cancer)&#xD;
&#xD;
          -  No concurrent digoxin or other medications for the treatment of heart failure&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O. Dillman, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Hoag Memorial Hospital Presbyterian</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <name_title>Robert O. Dillman</name_title>
    <organization>Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian</organization>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

